OptimizeRx (NASDAQ:OPRX) Given New $18.00 Price Target at Stifel Nicolaus

Key Points

• Stifel Nicolaus has raised the price target for OptimizeRx (NASDAQ:OPRX) from $16.00 to $18.00, indicating a potential upside of 5.16%.
• Shares of OptimizeRx saw a significant increase, trading up 33.3% to reach $17.12, while the stock's 1-year high is $18.22.
• Most analysts maintain a positive outlook on OptimizeRx, with three rating it as a hold and nine assigning a buy rating, leading to an average rating of "Moderate Buy".

OptimizeRx (NASDAQ:OPRX - Free Report) had its price objective increased by Stifel Nicolaus from $16.00 to $18.00 in a report released on Friday,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued research reports about the stock. B. Riley reaffirmed a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Wall Street Zen raised shares of OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. JMP Securities upped their target price on shares of OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a research note on Tuesday, May 13th. Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Roth Capital reaffirmed a "buy" rating on shares of OptimizeRx in a research note on Friday. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $11.81.

OptimizeRx Trading Up 1.4%

NASDAQ:OPRX traded up $0.22 during mid-day trading on Friday, hitting $16.40. The company had a trading volume of 389,943 shares, compared to its average volume of 383,862. The firm has a market cap of $303.40 million, a P/E ratio of -30.37, a P/E/G ratio of 5.77 and a beta of 1.33. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $18.22. The business's fifty day moving average is $13.59 and its two-hundred day moving average is $9.97. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.82 and a current ratio of 2.57.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative net margin of 9.42% and a positive return on equity of 4.50%. The business had revenue of $21.93 million for the quarter, compared to analyst estimates of $18.69 million. As a group, research analysts expect that OptimizeRx will post -0.33 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. American Century Companies Inc. lifted its stake in OptimizeRx by 9.6% in the first quarter. American Century Companies Inc. now owns 15,783 shares of the company's stock valued at $137,000 after acquiring an additional 1,387 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in OptimizeRx by 600.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company's stock worth $29,000 after purchasing an additional 1,818 shares during the period. Bank of New York Mellon Corp lifted its stake in OptimizeRx by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 89,538 shares of the company's stock worth $775,000 after purchasing an additional 1,826 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of OptimizeRx by 10.5% during the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company's stock worth $241,000 after buying an additional 2,636 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after buying an additional 2,797 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company's stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.